Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

May 2015

Specialty Pharmacy Program Updates 


Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications for both the Premium and Value formularies.

Name Indication Coverage Available From

Cerdelga (eliglustat) 

Cerdelga, an oral glucosylceramide synthase inhibitor, is indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.  Medical
Benefit
ICORE

Ibrance
(palbociclib) 

Ibrance is a kinase inhibitor used in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as the initial endocrine-based therapy for their metastatic disease.  Pharmacy Benefit Accredo

Lenvima
(lenvatinib) 

Lenvima is a kinase inhibitor used to treat patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Pharmacy Benefit Accredo

Signifor LAR
(pasireotide) 

Signifor LAR is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Medical
Benefit
Accredo

Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications for the Premium formulary only.

Name Indication Coverage Available From

Cosentyx (secukinumab)

Cosentyx is a human interleukin-17A antagonist  used to treat moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Pharmacy Benefit Accredo

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

New Updates Coming to HPHConnect

Harvard Pilgrim’s Preparations for ICD-10 Transition

CLINICIAN CORNER

Improvement in Coordination of Benefits Process

Coverage for Artificial Cervical Disc Replacement with Prior Authorization

Two New Medical Policies Now Available

Complex Case Management Services

Disease Management Programs that Reinforce Physician Treatment Plans

Specialty Pharmacy Program Updates

Reminder of Member Cost Sharing Waiver Policies

Collaboration among PCPs and Behavioral Health Providers

OFFICE ASSISTANT

2015 Update of the Home Care Seasonal Flu Vaccine Fee Schedule

Reminder: Ensure That Claims Contain Valid Codes

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator